Physician profile
Wendy E Smith
NPI 1730239153
$23,719.25
in general payments reported to CMS, 2019-2025
8 companies · $13K in 2025
The $13K reported for 2025 was more than what 85% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.62 · 2020: $11.14 · 2022: $2,340 · 2023: $8,344 · 2024: $108 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $7,150 · Travel and Lodging: $5,238 · Consulting Fee: $4,305 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,800 · Food and Beverage: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $7,150.00 |
| Travel and Lodging | $5,237.78 |
| Consulting Fee | $4,305.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,800.00 |
| Food and Beverage | $854.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $12,751.47 | 2025 | Palynziq |
| Horizon Therapeutics Plc | $8,283.97 | 2023 | Ravicti |
| Travere Therapeutics, INC. | $2,449.87 | 2019-2024 | |
| Pharmacosmos Therapeutics INC. | $124.31 | 2025 | Monoferric |
| Ptc Therapeutics, INC. | $59.95 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $30.00 | 2022 | |
| Illumina, INC. | $19.68 | 2025 | Genetic Disease Testing |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.